CAMRF (Camurus AB) ROCE %: 16.58% (As of Mar. 2026)


CAMRF Camurus AB CAMRF
79 GF Score
Price $54.00
GF Value $83.22
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB ROCE %?

Camurus AB CAMRF -3.57% 79 ROCE % is 16.58% as of Mar. 2026. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.22 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Camurus AB's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.58%.

Camurus AB  (OTCPK:CAMRF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Camurus AB ROCE % Related Terms

Camurus AB ROCE % Historical Data

* Premium members only.

The historical data trend for Camurus AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Camurus AB ROCE % Chart

Camurus AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.19 7.38 43.16 22.29 26.15

Camurus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.75 33.63 24.35 12.01 16.58
CAMRF
79GF Score
Camurus AB CAMRF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Camurus AB ROCE % Calculation

Camurus AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=101.01/( ( (342.013 - 39.93) + (510.031 - 39.509) )/ 2 )
=101.01/( (302.083+470.522)/ 2 )
=101.01/386.3025
=26.15 %

Camurus AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=79.564/( ( (510.031 - 39.509) + (532.148 - 42.811) )/ 2 )
=79.564/( ( 470.522 + 489.337 )/ 2 )
=79.564/479.9295
=16.58 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.58% mean?
Camurus AB (CAMRF) has a ROCE % of 16.58% as of Mar. 2026.
Is Camurus AB's ROCE % too high?
Camurus AB's current ROCE % is 16.58%. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's ROCE % compare to VRTX and REGN?
Camurus AB's ROCE % of 16.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Camurus AB's current ROCE % is 16.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.22, compared to a current price of $54.00 — trading 35.1% below its estimated fair value. The current ROCE % is 16.58%. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Camurus AB (CAMRF), the current ROCE % is 16.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 35.1% below its estimated GF Value™ of $83.22. GuruFocus considers Camurus AB to be Significantly Undervalued.

Key valuation signals for CAMRF:

  • ROCE %: 16.58%
  • GF Value™: $83.22 vs. price of $54.00 (35.1% below fair value)
  • GF Score™: 79/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score

Get the complete analysis for CAMRF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$83.22
GF Value